RT Journal Article
SR Electronic
T1 Reporting of medication adherence in randomized controlled trials of pharmacological interventions for SARS-CoV-2: a cross-sectional analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.30.22281709
DO 10.1101/2022.10.30.22281709
A1 Lee, C K
A1 Otunla, A
A1 Brennan,
A1 Aronson, JK
A1 Nunan, D
YR 2022
UL http://medrxiv.org/content/early/2022/10/30/2022.10.30.22281709.abstract
AB Background Adherence to pharmacological interventions in clinical trials is crucial for correct estimation of beneficial and adverse effects, including trials of SARS-CoV-2. The Template for Intervention Description and Replication (TIDieR) – a 12-item extension of the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines – includes two items (11 and 12) that address intervention adherence reporting in trial publications.Objective To assess compliance with TIDieR items 11 and 12 of randomised controlled trials (RCTs) of interventions in SARS-CoV-2 infection published in five selected journals during 2021.Methods We assessed SARS-CoV-2 pharmacological RCTs published in the Annals of Internal Medicine, The BMJ, JAMA, The Lancet, and The New England Journal of Medicine in 2021 for compliance with TIDieR items 11 and 12. Item 11 was assessed in two parts: 11a—how intervention adherence was assessed; 11b—if any strategies were used to maintain or improve how intervention adherence was maintained or improved. Item 12 assessed the extent to which the intervention was delivered as planned. We calculated raw adherence and proportional (weighted) adherence for pharmacological and comparator interventions where available.Results We found 75 eligible RCTs, of which 28 (37%) reported results related to SARS-CoV-2 vaccinations. Compliance with items 11a and 12 could be assessed in 71 of these 75. Of those 71 RCTs, 37 (52%, 95% confidence interval 40–64%) were compliant with reporting of item 11a. Seven RCTs had a strategy to assess compliance with item 11b, and only three (43%, 9–82%) of those complied with item 11b reporting. Of the 71 RCTs, 70 complied with reporting of item 12. Only one of the 71 RCTs (1.4%, 0–7.6%) fully complied with TIDieR items 11a, 11b, and 12. Compliance varied across journals.Conclusions RCTs of SARS-CoV-2 pharmacological interventions published in high-impact medical journals complied variably with reporting of intervention adherence, even though the journals endorse CONSORT. The implications for interpretation, application, and replication of findings based on these publications warrant consideration.Competing Interest StatementJKA is a member of the Centre for Business Innovation Medical Adherence and Digital Health Consortium, a non-profit-making discussion group, and has published papers on the subject of adherence to pharmacological interventions. CL, AO, IB, and DN have no competing interests to declare. Clinical Protocols https://osf.io/b96g3/files/osfstorage/620e56e911da1c0602f56ec0 Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data were openly available before initiation of this study. A list of the studies from which data were extracted is available here: https://osf.io/b96g3/files/osfstorage/635e587e0fac8308f979c6df https://osf.io/b96g3/files/osfstorage/635e587eb233120900430b40 The data can be found by searching for these studies through PubMed, where each study is openly availableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe repository of extracted data is available on the Open Science Framework. https://osf.io/b96g3/files/osfstorage/635e587e0fac8308f979c6df https://osf.io/b96g3/files/osfstorage/635e587eb233120900430b40